BI
NBIX icon

Binnacle Investments’s Neurocrine Biosciences NBIX Stock Holding History

Binnacle Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$7.86K Hold
56
– – ﹤0.01% 458
2025
Q2 		$7.04K Sell
56
-24
-30% -$2.75K ﹤0.01% 419
2025
Q1 		$8.85K Buy
+80
New +$10.1K 0.01% 351

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Binnacle Investments's NBIX Position: Q3 2025 in Review

Binnacle Investments held its Neurocrine Biosciences (NBIX) position steady in Q3 2025 at 56 shares worth $7.86K. The position accounts for ﹤0.01% of the portfolio, ranked #458.

Binnacle Investments first reported a position in NBIX in Q1 2025 and has held it in 3 quarters since. The position peaked at $8.85K in Q1 2025. 649 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • Binnacle Investments held 56 shares of Neurocrine Biosciences worth $7.86K as of Q3 2025.
  • Binnacle Investments left its Neurocrine Biosciences share count unchanged in Q3 2025.
  • Neurocrine Biosciences made up ﹤0.01% of Binnacle Investments's portfolio in Q3 2025, its #458 holding.
  • Binnacle Investments first reported a position in Neurocrine Biosciences in Q1 2025 and has held it in 3 quarters since.
  • Binnacle Investments's Neurocrine Biosciences position peaked at $8.85K in Q1 2025.
  • 649 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Binnacle Investments's 13F filing for Q3 2025, filed 14 Nov 2025.